Summit Therapeutics (SMMT) Cash from Operations (2017 - 2026)

Summit Therapeutics (SMMT) has reported Cash from Operations for 10 consecutive years, with 141124000.0 the latest figure, recorded in Q2 2026.

• Quarterly Cash from Operations fell 111.44% year-over-year to 141124000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 458433000.0 (down 121.59% YoY) and the FY2025 annual result came in at 322930000.0, down 127.25% from the prior year.
• Cash from Operations declined to 141124000.0 in Q2 2026 per SMMT's latest filing, from 122291000.0 in the prior quarter.
• Over the last five years, Cash from Operations for SMMT reached as high as 5191000.0 in Q4 2022 and fell as low as 141124000.0 in Q2 2026.
• A 5-year average of 47044055.56 and a median of 30215500.0 in 2024 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations soared 156.55% — and 2023, when it tumbled 474.86%.
• Year by year, Cash from Operations stood at 5191000.0 in 2022, then slumped by 474.86% to 19459000.0 in 2023, then plunged by 150.13% to 48673000.0 in 2024, then plunged by 109.43% to 101938000.0 in 2025, then plunged by 38.44% to 141124000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 141124000.0, 122291000.0, and 101938000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.